European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma", "sentences": [], "annotations": [], "relations": []}, {"offset": 36669, "infons": {"fpage": "773", "issue": "4", "lpage": "778", "name_0": "surname:Ferrajoli;given-names:A", "name_1": "surname:O'Brien;given-names:SM", "name_2": "surname:Cortes;given-names:JE", "pub-id_pmid": "12910522", "section_type": "REF", "source": "Cancer", "type": "ref", "volume": "98", "year": "2003"}, "text": "Phase II study of alemtuzumab in chronic lymphoproliferative disorders", "sentences": [], "annotations": [], "relations": []}, {"offset": 36740, "infons": {"fpage": "3554", "issue": "10", "lpage": "3561", "name_0": "surname:Keating;given-names:MJ", "name_1": "surname:Flinn;given-names:I", "name_2": "surname:Jain;given-names:V", "pub-id_pmid": "11986207", "section_type": "REF", "source": "Blood", "type": "ref", "volume": "99", "year": "2002"}, "text": "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study", "sentences": [], "annotations": [], "relations": []}, {"offset": 36865, "infons": {"fpage": "1613", "issue": "10", "lpage": "1616", "name_0": "surname:Calne;given-names:R", "name_1": "surname:Moffatt;given-names:SD", "name_2": "surname:Friend;given-names:PJ", "pub-id_pmid": "10589966", "section_type": "REF", "source": "Transplantation", "type": "ref", "volume": "68", "year": "1999"}, "text": "Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients", "sentences": [], "annotations": [], "relations": []}, {"offset": 36960, "infons": {"fpage": "1737", "issue": "1", "lpage": "1738", "name_0": "surname:Kyle;given-names:V", "name_1": "surname:Roddy;given-names:J", "name_2": "surname:Hale;given-names:G", "name_3": "surname:Hazleman;given-names:BL", "name_4": "surname:Waldmann;given-names:H", "pub-id_pmid": "1787497", "section_type": "REF", "source": "J Rheumatol", "type": "ref", "volume": "18", "year": "1991"}, "text": "Humanized monoclonal antibody treatment in rheumatoid arthritis", "sentences": [], "annotations": [], "relations": []}, {"offset": 37024, "infons": {"fpage": "69", "issue": "1", "lpage": "76", "name_0": "surname:Hale;given-names:G", "name_1": "surname:Jacobs;given-names:P", "name_2": "surname:Wood;given-names:L", "pub-id_pmid": "10918407", "section_type": "REF", "source": "Bone Marrow Transplant", "type": "ref", "volume": "26", "year": "2000"}, "text": "CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells", "sentences": [], "annotations": [], "relations": []}, {"offset": 37172, "infons": {"fpage": "120", "issue": "1", "lpage": "129", "name_0": "surname:Kirk;given-names:AD", "name_1": "surname:Hale;given-names:DA", "name_2": "surname:Mannon;given-names:RB", "pub-id_pmid": "12865797", "section_type": "REF", "source": "Transplantation", "type": "ref", "volume": "76", "year": "2003"}, "text": "Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H)", "sentences": [], "annotations": [], "relations": []}, {"offset": 37309, "infons": {"fpage": "754", "issue": "4", "lpage": "760", "name_0": "surname:Cull;given-names:GM", "name_1": "surname:Haynes;given-names:AP", "name_2": "surname:Byrne;given-names:JL", "pub-id_pmid": "10792280", "section_type": "REF", "source": "Br J\nHaematol", "type": "ref", "volume": "108", "year": "2000"}, "text": "Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity", "sentences": [], "annotations": [], "relations": []}, {"offset": 37496, "infons": {"fpage": "1616", "issue": "6", "lpage": "1623", "name_0": "surname:Ho;given-names:AY", "name_1": "surname:Pagliuca;given-names:A", "name_2": "surname:Kenyon;given-names:M", "pub-id_pmid": "15059843", "section_type": "REF", "source": "Blood", "type": "ref", "volume": "104", "year": "2004"}, "text": "Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab conditioning", "sentences": [], "annotations": [], "relations": []}, {"offset": 37708, "infons": {"fpage": "16", "issue": "1", "lpage": "24", "name_0": "surname:Martin;given-names:SI", "name_1": "surname:Marty;given-names:FM", "name_2": "surname:Fiumara;given-names:K", "name_3": "surname:Treon;given-names:SP", "name_4": "surname:Gribben;given-names:JG", "name_5": "surname:Baden;given-names:LR", "pub-id_pmid": "16758413", "section_type": "REF", "source": "Clin Infect Dis", "type": "ref", "volume": "43", "year": "2006"}, "text": "Infectious complications associated with alemtuzu